Up­dat­ed: Take­da bets $400M cash on col­orec­tal can­cer drug in boost to Chi­na's Hutchmed

Take­da is wa­ger­ing $400 mil­lion on what it sees as a promis­ing new treat­ment for col­orec­tal can­cer — one that’s been ap­proved in Chi­na for five years.

The deal gives Take­da ex­clu­sive rights to fruquin­tinib, an oral ty­ro­sine ki­nase in­hibitor of vas­cu­lar en­dothe­lial growth fac­tor re­cep­tor (VEG­FR) 1/2/3, every­where out­side of main­land Chi­na, Hong Kong and Macau. Hutchmed, the orig­i­nal de­vel­op­er of the drug, has al­ready lined up new drug sub­mis­sions in the US, EU and Japan for 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER